Glycoconjugate mucin secretion from conjunctival goblet cells is tightly regulated by nerves and specialized proresolving mediators (SPMs) to maintain ocular surface health. Here we investigated the actions of the SPM resolvin E1 (RvE1) ] i . RvE1 could be an important regulator of goblet cell glycoconjugate mucin secretion to maintain ocular surface health.
Introduction
The first defense a pathogen, allergen, or environmental pollutant encounters when challenging the eye is the tear film. The tear film is produced in part by the conjunctiva which is a mucous membrane that functions as a part of the innate immune system of the eye, and provides a critical barrier between the ocular surface and the environment. The conjunctiva is comprised of stratified epithelial cells, a basement membrane and stroma. Within the epithelial layer of the conjunctiva are goblet cells. Conjunctival goblet cells produce and secrete the high molecular weight glycoconjugate mucin MUC5AC, which protects the ocular surface by trapping pathogens, allergens, and environmental pollutants and removing them from the ocular surface by drainage through the nasolacrimal duct (Dartt and Masli, 2014; Jumblatt et al., 1999; Mantelli and Argueso, 2008) .
In uncontrolled inflammatory diseases like dry eye disease and allergic conjunctivitis, mucin secretion is dysregulated (Mantelli and Argueso, 2008; Govindarajan and Gipson, 2010; Contreras-Ruiz et al., 2013; McGilligan et al., 2013) . Patients with dry eye disease usually have decreased tear film mucin and may suffer from burning, itching and blurred vision. Studies also show substantially decreased quality of life for these patients (Uchino and Schaumberg, 2013) . Patients with allergic conjunctivitis have increased tear film mucins, but similarly to patients with dry eye, complain of symptoms including itching, redness and tearing. Vernal keratoconjunctivitis, a very severe form of allergic conjunctivitis, may even lead to vision loss (La Rosa et al., 2013) . Dry eye disease and allergic conjunctivitis both have dysregulated tear film mucin production and both are growing public health problems for which current treatments are limited (Gayton, 2009; Gomes, 2014) . Inflammation is crucial in order to remove pathogens, allergens, and environmental pollutants from the body. However, uncontrolled inflammation can occur without a pathogen, allergen, or tissue damage https://doi.org/10.1016/j.exer.2018.04.015 Received 4 January 2018; Received in revised form 18 April 2018; Accepted 23 April 2018 present, leading to unnecessary discomfort and tissue damage. In recent years, it has been established that there are lipid mediators which actively terminate the inflammation. These mediators are known as specialized pro-resolving mediators (SPMs) and consist of families termed resolvins, lipoxins, protectins and maresins (Serhan, 2014; Serhan and Chiang, 2013) . The present study focuses on the SPM resolvin E1 (RvE1), which is produced from the omega-3 fatty acid eicosapentanoic acid (EPA) (Serhan et al., 2004) . RvE1 induces intracellular signaling pathways through the ChemR23/ERV-1 receptor (Ohira et al., 2010) . ChemR23 has been detected earlier by immunohistochemistry in rat conjunctival goblet cells (Dartt et al., 2011) .
Numerous studies show that RvE1 reduces inflammation in the eye. We demonstrated that RvE1 blocks the pro-inflammatory leukotriene (LT) D 4 -stimulated increase in goblet cell secretion from cultured rat conjunctival goblet cells (Dartt et al., 2011) . In a murine model of dry eye disease, topical application of RvE1 decreased inflammatory markers and increased the number of goblet cells and tear production (Li et al., 2010; de Paiva et al., 2012) . In other studies, RvE1 decreased inflammation in the cornea (Lee et al., 2015; Rajasagi et al., 2011; Jin et al., 2009 ). The long acting RvE1 analog RX-10045 reduced postoperative complications after laser refractive surgery (Torricelli et al., 2014) . Furthermore, multiple studies indicate that a dietary intake of omega-3 fatty acids including EPA has a beneficial effect on dry eye disease (Miljanovic et al., 2005; Viau et al., 2009) . To date, RvE1 has been used in one clinical trial where an analog of RvE1 reduced symptoms in dry eye disease patients ). Studies on a molecular level, in animal models and a clinical trial implicate a role for RvE1 in terminating ocular surface inflammation.
Recent results from our group found that SPMs, not only play a part in terminating inflammation, but also have a physiological role in conjunctival goblet cells to maintain ocular surface health in the absence of disease. Amongst the SPMs that are effective in the conjunctiva are resolvin D1 (RvD1), aspirin-triggered RvD1 (AT-RvD1), and lipoxin A 4 (LXA 4 ). All these SPMs, on their own, increase the intracellular [Ca 2+ ] ([Ca   2+ ] i ) and stimulate glycoconjugate secretion Li et al., 2013; Hodges et al., 2017) . Both RvD1 and LXA 4 stimulate an increase in [Ca 2+ ] i through activation of phospholipase (PLC), phospholipase D (PLD), and phospholipase A2 (PLA2) Hodges et al., 2017) . Although numerous studies indicate that RvE1 can be a promising new treatment of ocular inflammatory diseases, the physiological functions of RvE1 in the eye to maintain health are unknown. In this study, we investigated the actions of RvE1 on glycoconjugate mucin secretion and [Ca 2+ ] i from cultured conjunctival goblet cells and the signaling pathways used by RvE1 to do so.
Materials and methods

Materials
RPMI-1640 cell culture medium, penicillin/streptomycin and Lglutamine were purchased from Lonza (Walkerville, IL). Fetal bovine serum (FBS) was from Atlanta Biologicals (Norcross, GA). UEA-1 and histamine were obtained from Sigma-Aldrich (St. Louis, MO).
RvE1 and RvD1 were purchased from Cayman Chemical (Ann Arbor, MI) or obtained from the Serhan lab. RvE1 or RvD1, in ethanol, was stored at −80°C, and diluted immediately before use in either RPMI medium or Krebs-Ringer bicarbonate buffer with HEPES (KRB-HEPES, 119 mM NaCl, 4.8 mM KCl, 1.0 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 , 10 mM HEPES, and 5.5 mM glucose (pH 7.40-7.45) ) to the desired concentrations (10 −8 M for RvD1 and 10 −9 M for RvE1) and added to the cells.
Ro-318220, U73122 and U73343, KN92 and KN93 were purchased from Tocris Bioscience (Ellisville, MO). Histamine, carbachol (CCh), aristolochic acid (aris acid), BAPTA, 2-APB, 1-butanol (1-but) and tbutanol (t-but) were from Sigma-Aldrich (St Louis, MO). Fura-2/AM and BAPTA/AM were from Life Technologies (Grand Island, NY). Amplex Red was from Invitrogen (Grand Island, NY).
Animals
Male Sprague-Dawley rats (125-150 g) (Taconic Farms, Germantown, NY) were used for all the experiments. The rats were anesthetized for 1 min in CO 2 before decapitation. The bulbar and forniceal conjunctiva were removed from both eyes. All experiments were in accordance with the National Institutes of Health guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978) . The animal protocol was approved by the Schepens Eye Research Institute Animal Care and Use Committee.
Cell culture
Goblet cells from male rats were grown in organ culture as described previously (Dartt et al., 2011; Lippestad et al., 2017; Li et al., 2013; Hodges et al., 2012a Hodges et al., , 2016a Hodges et al., , 2017 Shatos et al., 2001; Hayashi et al., 2012) . The conjunctiva was cut into small pieces, and placed in 6 well plates containing RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine and 100 μg/ml penicillin-streptomycin. After 5-7 days, the explants were removed and the cells trypsinized. First passage goblet cells were used in all experiments. Cells were seeded in either glass bottomed culture dishes for Ca 2+ -experiments or 24 well plates for glycoconjugate secretion experiments. To confirm that goblet cells predominated in the cell culture, immunohistochemistry was conducted using the lectin UEA-1 (which recognized goblet cell secretory products) and an antibody to cytokeratin 7 (detects goblet cell body) (Dartt et al., 2011; Li et al., 2012 Li et al., , 2013 Hodges et al., 2012a Hodges et al., , 2016a Hodges et al., , 2017 Shatos et al., 2001; Hayashi et al., 2012) . Ninety-five percent of cells cultured were goblet cells (data not shown).
Secretion
Cultured rat conjunctival goblet cells were trypsinized, passaged into 24 well plates, and grown to approximately 75% confluence. The cells were serum starved in serum free RPMI 1640 containing 0.5% bovine serum albumin (BSA) for 2 h before they were incubated with RvE1 (10 −9 M-10 −7 M) for 2 or 4 h. Histamine (10 −5 M) and RvD1
(10 −8 M) were used as controls. Basal conditions (e.g. no RvE1) included 0.04% ethanol, the highest concentration of ethanol present in any of the conditions. Ethanol had no significant effect on basal secretion (data not shown). In separate experiments, the cells were serum starved for 2 h before they were incubated with BAPTA/AM (10 −5 M) for 30 min followed by RvE1 (10 −9 M) or no additions for 2 h. U73122, PLC inhibitor, and the negative control, U73343, were added 15 min prior to RvE1-stimulation. 2-APB, an inositol 1,4,5-trisphosphate (IP 3 ) receptor antagonist, Ro 31-8220, a protein kinase C (PKC) inhibitor, and aristolochic acid (aris), a PLA 2 inhibitor were added 10 min before RvE1 stimulation for 2 h. 1-Butanol (1-but), a PLD inhibitor, and tertiary-but (t-but), the PLD negative control, were added 15 min before stimulation. KN93, a calcium/calmodulin-dependent protein kinase II (Ca 2+ /CaMK) inhibitor, or the inactive control KN92 were added 30 min before stimulation with RvE1 for 2 h.
The amount of goblet cell high molecular weight glycoconjugate secretion was measured using the lectin UEA-1 in an enzyme linked lectin assay (ELLA). UEA-1 binds to high molecular weight glycoproteins, including goblet cell mucin MUC5AC (Hodges et al., 2012a) . The amount of lectin-detected glycoconjugates was measured, as described previously (Dartt et al., 2011; Li et al., 2013; Hodges et al., 2012a Hodges et al., , 2016a Hodges et al., , 2017 Hayashi et al., 2012) . Glycoconjugate secretion is shown as fold increase above basal, which was set to 1.
Measurement of [Ca
Goblet cells were incubated for 1 h at 37°C with KRB-HEPES containing 0.5% BSA, 0.5 μM fura-2/AM, 8 μM pluronic acid F127 and 250 μM sulfinpyrazone. Calcium measurements were made with a ratio imaging system (In Cyt Im2; Intracellular Imaging, Cincinnati, OH) using wavelengths of 340 and 380 nm and an emission wavelength of 505 nm. For each experiment, at least five cells were selected and were followed for the entire experiment (approximately 2 min). Goblet cells were incubated with inhibitors as was done with glycoconjugate secretion before RvE1 was added. 
Statistical analysis
Results are presented as average ± SEM. One way ANOVA with Tukey post-hoc test or Student's t-test was used to perform statistical analysis, and p < 0.05 was considered statistically significant.
Results
RvE1 stimulates glycoconjugate secretion in rat conjunctival goblet cells
As the SPMs LXA 4 , RvD1 and AT-RvD1 each stimulate glycoconjugate secretion in rat goblet cells Hodges et al., 2017) , we investigated if RvE1 can similarly regulate goblet cell glycoconjugate secretion. As both histamine and RvD1 stimulate glycoconjugate secretion from rat conjunctival goblet cells, these compounds were used as positive controls for this experiment Hayashi et al., 2012) . Goblet cells were stimulated for 2 h with RvE1 at 10 Glycoconjugate secretion from rat conjunctival goblet cells was also measured 4 h after addition of RvE1, histamine, or RvD1. Only one concentration of RvE1, 10 −9 M, significantly increase in glycoconjugate secretion compared to basal after 4 h, with an increase of 1.6 ± 0.2 (p = 0.02) fold above a basal of 445.9 μg/ml (Fig. 1B) . Secretion stimulated by all other concentrations of RvE1 and RvD1 were decreased at 4 h compared to 2 h, though the values did not reach significance. In contrast, histamine-stimulated glycoconjugate secretion was unchanged from 2 to 4 h (p = 0.70). Thus, RvE1 stimulates conjunctival goblet cell high molecular weight glycoconjugate secretion, but is more effective at shorter time intervals of stimulation.
RvE1 increases [Ca
2+
] i in a concentration dependent manner in rat conjunctival goblet cells
In addition to increasing glycoconjugate secretion, RvD1, AT-RvD1 and LXA 4 also increase [Ca 2+ ] i in rat conjunctival goblet cells Hodges et al., 2017) . To determine if RvE1 elevates [Ca 2+ ] i in goblet cells, cultured cells were incubated with fura-2/AM, as described in 2.5 and stimulated with RvE1 10 −11 M to 10 −7 M. RvE1 increased [Ca 2+ ] i in a concentration-dependent manner ( Fig. 2A-C ] i is known to be a common stimulator of glycoconjugate mucin secretion in conjunctival goblet cells Hodges et al., 2017; Li et al., 2012; Dartt et al., 2000) . BAPTA/AM, an intracellular calcium chelator, was used to determinate whether RvE1 elevates [Ca 2+ ] i to increase glycoconjugate secretion. Cultured goblet cells were incubated with BAPTA/AM (10 −6 -10 −5 M) for 30 min before stimulation with RvE1 (10 −9 M). In these experiments, BAPTA did not affect basal glycoconjugate secretion (data not shown). RvE1 increased glycoconjugate secretion to 1.8 ± 0.3 (p = 0.02) fold above basal (Fig. 3) . BAPTA at 10 −6 blocked RvE1-induced glycoconjugate secretion and was 1.3 ± 0.3 fold above basal. BAPTA at 10 −5 M or 4 h (B). Glycoconjugate secretion was measured. Data are mean ± SEM from 4 independent experiments and shown as fold above basal, which set to 1. * indicates significant difference from basal.
significantly decreased RvE1-stimulated secretion and was 1.1 ± 0.3 fold above basal (p = 0.01) (Fig. 3) ] i increase was significantly decreased to 133.2 ± 63.6 nM using 2-APB 10 −6 M ( Fig. 4C and D ] i was significantly inhibited to 199.1 ± 50.4 nM (p = 0.03) by Ro 31-8220 10 −6 M ( Fig. 4G and H) . Based on all these experiments, RvE1 appears to activate the PLC pathway producing IP 3 and activating PKC to increase [Ca 2+ ] i. in goblet cells. -10 −5 M) for 30 min before stimulation with RvE1 (10 −9 M). Glycoconjugate secretion was measured. Data are mean ± SEM from 4 independent experiments and shown as fold above basal, which set to 1. * indicates significant difference from basal; # indicates significance from RvE1 alone.
RvE1 activates PLD to increase [Ca
2+
] i in cultured rat goblet cells
As other SPMs also use PLD to increase [Ca 2+ ] i and glycoconjugate secretion Hodges et al., 2017) , we investigated the effects of RvE1 on PLD activation. Goblet cells were incubated with either the PLD inhibitor 1-but or the negative control t-but, both at 0.3%. In these experiments, RvE1 (10 −9 M) alone significantly in- ] i increase ( Fig. 5A and B) . Thus, we conclude that RvE1 activates the PLD pathway in rat conjunctival goblet cells. ] i is shown in B, D, F, and H. Data are mean ± SEM from 3 (A and B), 7 (C and D), 6 (E and F) and 6 (G and H) independent experiments. * indicates significant difference from basal; # indicates significance from RvE1 alone. ] i is shown in B. Data are mean ± SEM from 5 independent experiments. * indicates significant difference from basal; # indicates significance from RvE1 alone. /CaMK (Fig. 7A and B) .
3.8. RvE1 uses PLC, PLD, and PLA2 but not Ca 2+ /CaMK to stimulate glycoconjugate secretion in rat conjunctival goblet cells As RvE1-stimulated increase in [Ca 2+ ] i was dependent on activation of the PLC, PLD, and PLA2 pathways, the effect of inhibitors of these pathways on glycoconjugate secretion was determined. Cells were preincubated with inhibitors as described in 2.4, followed by RvE1 (10 −9 M). RvE1 alone significantly increased glycoconjugate secretion 2.1 ± 0.2 fold above basal. U73122, but not U73343, significantly inhibited RvE1 stimulated secretion to 1.1 ± 0.1 fold above basal (Fig. 8) . 2-APB and Ro 31-8220 also significantly inhibited RvE1 stimulated secretion to 1.3 ± 0.1 and 1.1 ± 0.3 fold above basal, respectively. 1-Butanol, the inhibitor of PLD, but not the negative control t-but, significantly inhibited RvE1-stimulated secretion as did aris acid, a PLA2 inhibitor (Fig. 8) . Inhibition of Ca 2+ /CaM-dependent kinase with KN93 did not alter RvE1-stimulated glycoconjugate secretion (Fig. 8) .
Discussion
Herein we found that RvE1 stimulates glycoconjugate secretion from conjunctival goblet cells and did so by increasing [Ca 2+ ] i , and activation of the PLC, PLD, and PLA 2 signaling pathways. The PLC downstream molecules IP 3 and PKC were also activated by RvE1 (Fig. 9) .
In multiple types of chronic inflammatory diseases RvE1 is an active component of the resolution of inflammation (Hasturk et al., 2006; Aoki et al., 2010; Salic et al., 2016; Herrera et al., 2015; Kim et al., 2012; Haworth et al., 2008) . Here, we presented supportive results that RvE1 may also regulate glycoconjugate secretion in conjunctival goblet cells in physiological conditions to maintain ocular surface health. Our results are consistent with earlier studies of the SPMs RvD1 and LXA 4 , which we showed also play a role in stimulating conjunctival goblet cell secretion under normal, physiological conditions. Similarly to RvE1, RvD1 and LXA 4 also stimulate glycoconjugate mucin secretion thorough an increase in [Ca 2+ ] i Hodges et al., 2016b) . RvE1 binds to the receptor ERV-1/ChemR23 (Arita et al., 2007) , RvD1 activates DRV1/GPR32 (in humans) and ALX/FPR2 (Krishnamoorthy et al., 2010 (Krishnamoorthy et al., , 2012 and LXA 4 stimulates ALX/FPR2 . Although RvE1, RvD1, and LXA 4 activate different receptors, they act in a surprisingly similar manner. All the SPMs studied activated PLC, PLD and PLA 2 pathways when interacting with goblet cells from the conjunctiva. The only significant difference we found was that RvD1 and LXA 4 also induced [Ca 2+ ] i through Ca 2+ / CaMK. Our results indicate that SPMs have a common regulating function on goblet cell glycoconjugate mucin secretion, which is key in maintaining a healthy ocular surface. A physiological role for the SPMs is strengthened by LXA 4 and RvD1 being found in emotional tears from human (English et al., 2017) . Although RvE1 was not identified in tears ] i is shown in B. Data are mean ± SEM from 4 independent experiments. * indicates significant difference from basal. Fig. 8 . Inhibition of PLC, PLD, and PLA2, but not Ca2+/Cam Kinase, blocks RvE1-stimulated glycoconjugate secretion in rat conjunctival goblet cells. Cultured goblet cells were incubated with U73122, U73343, 2-APB, Ro 31-8220, 1-but, t-but, aris acid, KN93, or KN92 before stimulation with RvE1 (10 −9 M). Glycoconjugate secretion was measured. Data are mean ± SEM from 4 independent experiments and shown as fold above basal, which set to 1. * indicates significant difference from basal; # indicates significance from RvE1 alone.
this may reflect the nutritional status of EPA of the individuals since 18-HEPE, the RvE1 precursor, was present in tears from males. Hence, RvE1 could still be effective in maintaining ocular surface health if added topically to the tear film. None of the inhibitors gave a complete blockage of RvE1-stimulated [Ca 2+ ] i . RvE1 works through several different signaling pathways.
Here, we studied three possible pathways that RvE1 could activate and found that all three were used by RvE1. Although one pathway may be inhibited, [Ca 2+ ] i can still be increased by RvE1 through other pathways, and stimulate to glycoconjugate secretion. This redundancy signifies the importance of RvE1 as a regulator of glycoconjugate mucin secretion.
When activation of the PLC pathway was studied using the PLC inhibitor U73122 and its negative control U73343, the negative control inhibited RvE1-induced [Ca 2+ ] i increase more than the inhibitor. A similar problem occurred when U73343 also inhibited RvD1-induced [Ca 2+ ] i increase . In contrast, U73122 inhibited the [Ca 2+ ] i increase induced by the cholinergic agonist carbachol, but the negative control U73343 did not . There are several possibilities for the difference between RvE1, RvD1, and carbachol. First, even though all three agonists each bind to G protein coupled receptors, the receptors are different and thus the coupling to PLC could differ. Perhaps different Gα proteins are used. Cholinergic agonists activate three of the different muscarinic receptors, M 1 AChR, M 2 AChR, and M 3 AChR (Rios et al., 1999 Kanno et al., 2003; Hodges et al., 2012b) . These receptors usually act through Gαq (Zenko and Hislop, 2017) . In contrast, RvE1 can use Gαi (Jo et al., 2016 The goal of studying RvE1 in goblet cells is to determine if it may be used to preserve ocular surface homeostasis and as a treatment of ocular inflammatory diseases. We found that RvE1 increased glycoconjugate secretion after 2 h, not at 4 h. This suggests that RvE1 has a short, but potent, action on regulating goblet cell secretion. Similar results were obtained for RvD1 and AT-RvD1, where glycoconjugate secretion was measured every hour for 0-4 h. Peak secretion was observed for both RvD1 and AT-RvD1 after 1 h . This time dependency is similar to that of EGF but shorter than the effect of histamine that was still effective after 4 h in rat conjunctival goblet cells (Hayashi et al., 2012; Hodges et al., 2012a) . Thus, RvE1 could function to provide short-term stimulation of high molecular weight glycoconjugates including MUC5AC secretion without overproducing mucin that can be harmful to the ocular surface.
The data presented in this manuscript along with studies by Lippested et al. using RvD1 and Hodges et al. (2017) using LXA 4 , support the hypothesis that these SPMs play a dual role in the conjunctival goblet cells. The first role is to maintain homeostasis in normal, non-inflamed conjunctiva. In support of this, we demonstrated that resolvins RvE1, RvD1, and LXA 4 alone stimulate [Ca 2+ ] i and secretion. In these experiments, the resolvins were added (with no other additions) and [Ca 2+ ] i or secretion were measured. The second role is the resolution of inflammation and as such they inhibit histamine-and leukotriene-stimulated increase in [Ca 2+ ] i and secretion. This was demonstrated by incubation of goblet cells for 30 min with resolvins prior to addition of either histamine or leukotrienes (Dartt et al., 2011; Li et al., 2013) . In summary, RvE1 stimulates conjunctival goblet cells to secrete high molecular weight glycoconjugates including MUC5AC secretion by increasing [Ca 2+ ] i . which in turns activates the PLC, PLD and PLA 2 signaling pathways. Previous results have shown that RvE1, like RvD1 and LXA 4, counter-regulate inflammatory mediator induced glycoconjugate secretion (Dartt et al., 2011; Hodges et al., 2016a) . RvE1, RvD1 and LXA 4 appear to act in similar ways to regulate glycoconjugate mucin secretion during physiological conditions using different GPCR to evoke intracellular signals. We conclude that RvE1, as well as other SPMs, help to maintain stable, normal glycoconjugate mucin production in the ocular surface. Thus, RvE1 may be useful both to maintain ocular surface health and as a treatment of ocular surface inflammatory diseases. 
